CCM
HRTX icon

Cadence Capital Management’s Heron Therapeutics HRTX Stock Holding History

Cadence Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-15,227
Closed -$275K – 634
2016
Q2 		$275K Sell
15,227
-305
-2% -$5.95K 0.02% 535
2016
Q1 		$295K Hold
15,532
– – 0.02% 560
2015
Q4 		$415K Buy
+15,532
New +$415K 0.03% 498

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Cadence Capital Management's HRTX Position: Q3 2016 in Review

Cadence Capital Management sold out of Heron Therapeutics (HRTX) in Q3 2016, closing a stake of 15,227 shares — an estimated $275K sold.

Cadence Capital Management first reported a position in HRTX in Q4 2015 and held it in 3 quarters. The position peaked at $415K in Q4 2015. 91 funds tracked by Wall St. Rank hold HRTX as of Q3 2016.

  • Cadence Capital Management reported no remaining Heron Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Cadence Capital Management sold 15,227 Heron Therapeutics shares in Q3 2016, an estimated $275K.
  • Cadence Capital Management first reported a position in Heron Therapeutics in Q4 2015 and held it in 3 quarters.
  • Cadence Capital Management's Heron Therapeutics position peaked at $415K in Q4 2015.
  • 91 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2016.

Based on Cadence Capital Management's 13F filing for Q3 2016, filed 10 Nov 2016.